Clinical Results临床的的结果.pptVIP

Core Clinical Results (CE) A-HeFT―Results and Conclusions Clyde Yancy, MD Professor of MedicineUniversity of Texas SouthwesternMedical Center at Dallas A-HeFT Efficacy Primary Endpoint—Composite Score? Components of Primary Composite EndpointA-HeFT 43% Decrease in Relative Risk of Mortality Cause-Specific MortalityA-HeFT First Hospitalization for HF—Event Rate BiDil? Decreases Relative Risk of First HF Hospitalization by 39% First HF Hospitalization Event Rates and Total Days in Hospital for HF HF Hospitalizations BiDil? Decreases Relative Risk of Mortality or First HF Hospitalization by 37% MLHF QuestionnaireChange in QoL Score at 6 Mo MLHF QuestionnaireChange in QoL From Baseline? Subgroup Analyses for the Primary Endpoint Composite Score (1) Subgroup Analyses for the Primary Endpoint Composite Score (2) Subgroup Analyses of Hazard Ratio for All-Cause Mortality (1) Subgroup Analyses of Hazard Ratio for All-Cause Mortality (2) Subgroup Analyses of HR for First HF Hospitalization (1) Subgroup Analyses of HR for First HF Hospitalization (2) Change in Blood Pressure From Baseline Effect of BP Lowering on BiDil? Treatment Effects Summary of BiDil? Efficacy BiDil is efficacious in the treatment of symptomatic heart failure in black patients: Decreases the risk of mortality Decreases hospitalization for HF Risk for first hospitalization Number of hospitalization Days in the hospital Improves quality of life A-HeFTClinical Safety Adverse Events AEs of Special Interest Most Frequent ≥ 1% Serious AEsSafety Population Patients in the Analysis Populations Conclusion Summary of BiDil? Efficacy and Safety A-HeFT confirms the hypothesis generated from V-HeFT I and V-HeFT II BiDil is efficacious in the treatment of HF in black patients: Increases survival by 43% Decreases hospitalization for HF Risk for first hospitalization by 39% Number of hospitalizations by 31% Days in the hospital by 42% Improves quality of life BiDil has a favorable safety profile for the